Here's Why Steris (STE) is a Strong Growth Stock

Zacks has introduced its Style Scores (Value, Growth, Momentum, and a combined VGM), which provide A-F ratings to complement the proprietary Zacks Rank, aiming to help investors identify stocks with higher outperformance potential. These scores are best utilized alongside a Zacks Rank of #1 or #2, or a strong #3 (Hold) if Style Scores are A or B. As an illustration, STERIS plc (STE), despite holding a Zacks #3 (Hold) rank, is highlighted due to its 'A' ratings in both VGM and Growth Style Scores, supported by a 9.8% forecasted earnings growth and recent upward analyst revisions, suggesting it warrants investor consideration as a growth opportunity.

Analysis

STERIS plc (STE) presents a nuanced investment profile, characterized by strong underlying growth indicators that contrast with its neutral Zacks #3 (Hold) rating. The company's key strengths, as highlighted by the Zacks Style Score system, are its 'A' ratings for both overall VGM (Value, Growth, Momentum) and for the Growth component specifically. This positive outlook is substantiated by a forecast for 9.8% year-over-year earnings growth for the current fiscal year. Furthermore, analyst sentiment for the forward-looking fiscal 2026 appears to be improving, with two analysts revising earnings estimates upward in the last 60 days. This has resulted in a $0.10 increase in the Zacks Consensus Estimate to $10.12 per share. The company's operational consistency is underscored by its track record of delivering an average positive earnings surprise of 2%. The central thesis is that while the overarching 'Hold' rank suggests a neutral short-term outlook, the robust growth metrics signal potential upside that may not be fully priced in.

Key Decisions for Investors

• Growth-oriented investors should consider STERIS plc as a potential opportunity, given its 'A' grade for growth, 9.8% forecasted earnings expansion, and positive analyst estimate revisions, which may not be fully reflected in its neutral 'Hold' rating.
• Investors should closely monitor upcoming earnings releases to validate the forecasted growth trajectory and to see if performance aligns with the revised fiscal 2026 consensus estimate of $10.12 per share.
• While the growth metrics are compelling, the Zacks #3 (Hold) rank warrants some caution, suggesting that investors should weigh the strong fundamental outlook against the factors that are currently constraining a higher-tier 'Buy' recommendation.